BAVAC Stock Overview
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Bavarian Nordic A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr.156.90 |
52 Week High | kr.214.40 |
52 Week Low | kr.135.38 |
Beta | 1.33 |
1 Month Change | 1.57% |
3 Month Change | n/a |
1 Year Change | -16.07% |
3 Year Change | -41.26% |
5 Year Change | 11.40% |
Change since IPO | 142.32% |
Recent News & Updates
Recent updates
Shareholder Returns
BAVAC | GB Biotechs | GB Market | |
---|---|---|---|
7D | 0% | 4.3% | 1.7% |
1Y | -16.1% | -26.1% | 1.4% |
Return vs Industry: BAVAC exceeded the UK Biotechs industry which returned -26.1% over the past year.
Return vs Market: BAVAC underperformed the UK Market which returned 1.4% over the past year.
Price Volatility
BAVAC volatility | |
---|---|
BAVAC Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 7.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: BAVAC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BAVAC's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 1,379 | Paul Chaplin | www.bavarian-nordic.com |
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.
Bavarian Nordic A/S Fundamentals Summary
BAVAC fundamental statistics | |
---|---|
Market cap | kr.11.91b |
Earnings (TTM) | kr.1.48b |
Revenue (TTM) | kr.7.06b |
8.1x
P/E Ratio1.7x
P/S RatioIs BAVAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BAVAC income statement (TTM) | |
---|---|
Revenue | kr.7.06b |
Cost of Revenue | kr.1.90b |
Gross Profit | kr.5.16b |
Other Expenses | kr.3.69b |
Earnings | kr.1.48b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
Earnings per share (EPS) | 18.93 |
Gross Margin | 73.07% |
Net Profit Margin | 20.89% |
Debt/Equity Ratio | 0.2% |
How did BAVAC perform over the long term?
See historical performance and comparison